- May 22, 2013
- 08:59 AM CET
- search
- T&C's
- Disclaimer
- PRIVACY POLICY
- Imprint
- RSS
- ©2013 EVOTEC
- Loading...
Overview of Product development partnerships
Evotec's clinical programmes are almost exclusively developed in partnerships with pharmaceutical companies.
| Partner | Indication | Status | Next milestone | |
| Teva/Andromeda | Type 1 Diabetes | Diapep277, synthetic peptide modulator | Second Phase III recruitment closed | Final Phase III data |
| Roche | Alzheimer's Disease | MAO-B inhibitor | Phase II recruiting | Completion of Phase II, Phase III start |
| JingXin | Insomnia | EVT201, GabaA | Phase II | Phase IIb start |
| Conba Pharmaceutical Co., Ltd. | Inflammation | EVT401 | Phase I/II | Phase II start |
| Janssen Pharmaceuticals | Treatment resistant depression | EVT100 series | Phase I/II | Confirmation of pre-clinical study/Phase II start |
| Pfizer | Pain | TRPV1 antagonist | Pre-clinical | Phase I start |
| Boehringer Ingelheim | Type 2 Diabetes | Insulin Sensitizer | Research | Pre-clinical |
| Janssen (CureBeta) | Type 1 and 2 Diabetes | Research | Pre-clinical | |
| MedImmune/AstraZeneca | Type 1 and 2 Diabetes | EVT770 | Research | Pre-clinical |
Development partnerships
Janssen Pharmaceuticals: EVT100 series
License agreement regarding Evotec's NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression.
- read moreAndromeda/Teva: DiaPep277
Development partnership with Andromeda on DiaPep277
- read moreRoche: MAO-B inhibitor against Alzheimer’s disease
Exclusive agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease
- read moreJingxin Pharma: EVT201
GABAA Receptor Partial Positive Allosteric Modulator- Insomnia
- read moreEVT401 - P2X7-Antagonist
In August 2011 Evotec partners P2X7 antagonist programme, EVT401, to a top tier global animal health company
In May 2012 Evotec grants exclusive rights on EVT401 in China to Conba Pharmaceutical
- read morePfizer: TRPV1 antagonist
VR1 antagonist program
- read moreBoehringer Ingelheim: Insulin Sensitizer
An integrated discovery alliance with Boehringer Ingelheim was signed
- read moreJanssen (CureBeta)
Evotec AG licensed a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells to Janssen Pharmaceuticals, Inc.
- read moreMedImmune/AstraZeneca: EVT770
License and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca) to develop EVT770
- read more